BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Nemolizumab: trial readouts and FDA decisions

1 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 2 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: Galderma R&D. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12 est.P2Galderma R&DNCT07074977 Proof of Concept Study to Assess the Pharmacokinetics/Pharmacodynamics of Nemolizumab in Adults With Chronic Pruritus of Unknown Origin (CPUO)Chronic Pruritus of Unknown Originactive not recruiting50

Readouts, last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-10-26 est.P3Galderma R&DNCT04204616 A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)Prurigo Nodularisactive not recruiting500
2026-08-31P3Galderma R&DNCT03989206 Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic DermatitisModerate-to-Severe Atopic Dermatitiscompleted1935

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.